Jiaqiang Jiang
Member of the Nanfang Hospital gastric-cancer surgery team that traced how a tumor-enriched gut bacterium rewires CD8+ T cells through an mTOR-linked checkpoint to blunt anti-PD-1 therapy.
Department of General Surgery · Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor · Nanfang Hospital, Southern Medical University · Guangzhou, China
Jiaqiang Jiang works in the gastrointestinal-tumor surgery group at Nanfang Hospital (Southern Medical University, Guangzhou) led by Yanfeng Hu. In the study behind this entry, the team found that the bacterium Streptococcus anginosus is enriched in gastric tumors that fail to respond to PD-1 checkpoint blockade, and that it produces a metabolite, kynurenic acid, which pushes up integrin α2 (ITGA2) on CD8+ T cells. ITGA2 in turn dampens an mTOR-dependent signaling step, keeping cathepsin V high and interferon-γ/granzyme B output low — effectively disarming the cytotoxic T cells the immunotherapy needs to work. Blocking ITGA2 restored T-cell killing activity and resensitized tumors to PD-1 blockade.
This is Jiang's only study currently in the Atlas under this name. PubMed shows the same Jiang, with the identical Nanfang Hospital affiliation, as a co-author on at least two other 2026 papers from the same lab on gut-microbiota–immune crosstalk in gastrointestinal cancers, suggesting a working researcher embedded in this specific research line rather than a one-off contributor.
Milestones in the Atlas
| Year | Evidence | Study |
|---|---|---|
| 2026 | A | Microbiota-associated kynurenic acid drives PD-1 blockade resistance through an ITGA2-mTOR-CTSV axis in gastric cancer. REN2026 Co-author on the Nanfang Hospital team that identified the Streptococcus anginosus–kynurenic acid–ITGA2–mTOR–cathepsin V axis driving PD-1 blockade resistance in gastric cancer. |
Co-authors in the Atlas
People with a profile here who share at least one study with Jiaqiang Jiang.
- Xiang Yu Member of Yanfeng Hu's gastric-cancer lab who contributed to a study showing how a microbiota-linked metabolite, kynurenic acid, drives resistance to PD-1 blockade